Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinorencel in CD19+ Relapsed/Refractory DLBCL
NCT06047197Phase 1Recruiting
- Sponsor
- Immunotech Biopharm
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-T-19 in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Immunotech Biopharm. Primary endpoints: Maximum Tolerated Dose at 28 days and Adverse Events Safety at 2 years. Started Sep 2023; status: recruiting.
02
Drugs
CAR-T-19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06047197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047197.